Clinical trials: Psychological Disorders
Restless Legs Syndrome, End-Stage Renal Disease
A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis
This is a sleep laboratory study to evaluate the efficacy and safety of Rotigotine in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysis.
- Trial name
- NCT01537042
- Testing
- Rotigotine
- Where
- 15 sites in United States, Austria and 4 more
- Volunteers
- 30 people
- Sponsor
- UCB BIOSCIENCES GmbH
Impotence
Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection
Study to evaluate the safety and effectiveness of 2.5 mg and 5 mg tadalafil when taken by men with diabetes mellitus who have problems getting and maintaining an erection.
- Trial name
- NCT00547183
- Testing
- tadalafil
- Where
- Germany
- Volunteers
- 298 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder
Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)
Generalized anxiety disorder affects about 6.8 million adults in the United States, therefore its treatment is of major public health interest.
- Trial name
- NCT05023759
- Testing
- Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Formula30A LLC
Sleep Deprivation, Sleepiness
Shift Hours' Impact on Fatigue and Tracking of Eye Dynamics
The goal of this clinical trial is to learn how night shift-induced sleep debt affects oculomotor patterns, attentional state, and diagnostic performance in emergency radiologists.
- Conditions
- Sleep Deprivation, Sleepiness, Eye-Tracking Technology, Radiologists
- Trial name
- SHIFTED (NCT07192380)
- Testing
- Electroencephalogram, Actigraphy, Eye Tracking
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- IMADIS Technologies et Services
Heart Failure, Heart Failure, Systolic
COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
The purpose of this study was to determine the effect of sacubitril/valsartan (LCZ696) vs. Enalapril on improvement in erectile function and ability in male patients with chronic heart failure with reduced ejection fraction and…
- Conditions
- Heart Failure, Heart Failure, Systolic, Erectile Dysfunction
- Trial name
- CONFIDENCE-HF (NCT03917459)
- Testing
- LCZ696, Enalapril
- Where
- 13 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"
The aim of this study is observation, in an Italian real-world setting, of metabolic effects in patients with schizophrenia who will switch from any mono-therapy or poly-therapy antipsychotic regimen to monotherapy with…
- Trial name
- SWITCH (NCT04312503)
- Testing
- Lurasidone, aripiprazole, olanzapine, quetiapine or risperidone
- Where
- 18 sites in Italy
- Volunteers
- 95 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Alzheimer Disease
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early…
- Trial name
- ALTITUDE-AD (NCT06335173)
- Testing
- sabirnetug
- Where
- 68 sites in United States, Canada and 3 more
- Volunteers
- 542 people
- Sponsor
- Acumen Pharmaceuticals
Alzheimer's Disease
Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia
The purpose of this study is to determine the safety, tolerability and effect of JNJ-54861911 on level of amyloid-beta in Cerebrospinal Fluid (CSF) and plasma following 4 weeks of treatment in Japanese participants asymptomatic…
- Trial name
- NCT02360657
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 50 mg
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
F17464 in Acute Schizophrenia Trial
The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia.
- Trial name
- FAST (NCT02151656)
- Testing
- F17464
- Where
- 27 sites in France, Hungary and 3 more
- Volunteers
- 158 people
- Sponsor
- Pierre Fabre Medicament
Depression, Anxiety
Meru Health Program for Cancer Patients With Depression and Anxiety
The primary objective of this study is to evaluate clinical outcomes among people with cancer who participate in a 12-week therapist-supported digital mental health intervention (DMHI) called the Meru Health Program (MHP).
- Trial name
- NCT05588622
- Testing
- Meru Health Program
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Meru Health, Inc.
Erectile Dysfunction
A Clinical Trial to Investigate the Efficacy and Safety of Tongkat Ali Maca Plus
This was a randomized, double blind, placebo-controlled, Three-arm, multicenter, parallel groups, interventional phase II clinical trial evaluating the efficacy, and safety of a herbal medicinal product of dried roots of Eurycoma…
- Trial name
- NCT05347329
- Testing
- Tongkat Ali Maca Plus
- Where
- Egypt
- Volunteers
- 197 people
- Sponsor
- Natural Wellness Egypt
Obstructive Sleep Apnea, Excessive Sleepiness
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA
This trial is a randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of JZP-110 on driving performance in subjects with excessive sleepiness due to obstructive sleep apnea.
- Trial name
- NCT02806895
- Testing
- JZP-110
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- Jazz Pharmaceuticals
Huntington's Disease
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months).
- Trial name
- NCT00387270
- Testing
- Dimebon
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medivation, Inc.
Frontotemporal Dementia
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
- Trial name
- NCT05483322
- Testing
- LAM-002A
- Sponsor
- IRulya Therapeutics Inc.
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
The purpose of this study is to assess changes in ADHD symptoms and tolerability of medication in children and adolescents switching from a stimulant to atomoxetine.
- Trial name
- NCT00485875
- Testing
- Atomoxetine Hydrochloride
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Treatment Resistant Depression
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the…
- Trial name
- NCT04519957
- Where
- 8 sites in United States, Czechia and 3 more
- Volunteers
- 66 people
- Sponsor
- COMPASS Pathways
ADHD
Guided ADHD Therapy for Managing the Extent and Severity of Symptoms
The objective of this study is to assess the safety and effectiveness of an at-home, game-based digital therapy for treating adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- GAMES (NCT05296473)
- Testing
- ADHD Therapy, Control Therapy
- Where
- 13 sites in United States
- Volunteers
- 560 people
- Sponsor
- Lumos Labs, Inc.
Major Depressive Disorder
Open-Label of SPN-820 in Adults With Major Depressive Disorder
This study will evaluate of the efficacy and safety of SPN-820 in Adults With Major Depressive Disorder (MDD)
- Trial name
- NCT06235905
- Testing
- NV-5138
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Navitor Pharmaceuticals, Inc.
Treatment-Resistant Depression
Efficacy and Safety of TAK-653 in Treatment-Resistant Depression
The purpose of this study is to evaluate the efficacy of TAK-653 compared with placebo in maintaining the effect of ketamine treatment on depressive symptoms.
- Trial name
- NCT03312894
- Testing
- TAK-653
- Sponsor
- Millennium Pharmaceuticals, Inc.
Anxiety
Pilot Study to Assess the Effect of a Probiotic Blend on Moderate Self-reported Anxiety.
This study evaluates the efficacy of a multistrain probiotic administered in the form of a capsule in the management of moderate self-reported anxiety in adults aged 18-65
- Trial name
- Anx (NCT05562752)
- Testing
- Probiotic
- Where
- Ireland
- Volunteers
- 100 people
- Sponsor
- The Archer-Daniels-Midland Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.